{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-027380","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.464132+00:00","generated_at":"2026-05-31T08:37:07.199827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Windtree Q2 net loss $12M ($20.91/shr), istaroxime data expected Q3 2024","bullets":["Net loss of $12.0M ($20.91 per share) on 0.6M shares; operating loss $11.5M vs. $6.8M in Q2 2023.","R&D expense $9.9M (incl. $7.5M non-cash Varian asset acquisition cost) vs. $1.8M; G&A $1.6M vs. $2.4M.","Cash $1.8M, current liabilities $8.8M; substantial doubt about going concern disclosed.","Closed July transactions for $13.9M gross proceeds ($4.4M new funding, $9.5M note extinguishment); $35M equity line secured.","Istaroxime Phase 2 SEISMiC study enrollment near complete, topline by end of Q3 2024; board added Saundra Pelletier, Jed Latkin."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-027380","json":"https://secwatch.observer/filing/0001437749-24-027380.json","markdown":"https://secwatch.observer/filing/0001437749-24-027380.md","text":"https://secwatch.observer/filing/0001437749-24-027380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774924027380/0001437749-24-027380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774924027380/wint20240529_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:37:07.199827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}